Analyst Ratings for Vanda Pharmaceuticals (VNDA)
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
2/25/2022 | Jefferies | Chris Howerton | Downgrade | Hold (Buy) |
12.00 (24.00) |
13.07 (3.75) |
-71.31% | Details |
5/12/2021 | BofA Securities | N/A | New Coverage | Buy (N/A) |
22.00 (N/A) |
17.83 (3.75) |
-78.97% | Details |
VNDA Ratings News
- UPDATE: Jefferies Downgrades Vanda Pharmaceuticals (VNDA) to Hold
- UPDATE: BofA Securities Starts Vanda Pharmaceuticals (VNDA) at Buy Upside to Come From Under the Radar Candidates
- Vanda Pharmaceuticals (VNDA) PT Raised to $24 as Jefferies Sees an Unusual Opportunity for Social Impact Investors
- See More